Figure 2. Efficacy of ValloVax across histologically distinct tumors.

GL-261 A. or CT-26 B. tumor cells were inoculated at time of vaccination or 10 days prior to vaccination, respectively, at a concentration of 1.7 × 10(6) or 5 × 10(5) cells per mouse. For GL-261 experiments, ValloVax was administered weekly, whereas for CT-26 experiments, vaccination was administered at day 10 post tumor inoculation and day 17. Tumor growth was assessed at the indicated timepoints.